Editorial

Engineering the Future of Cancer Care: How Next-Generation Antibody-Drug Conjugates (ADCs) Are Shaping Oncology and Beyond

Reviewing the Key Trends and Insights from the ADC Linker & Conjugation Summit

The Opportunity to go Beyond “chemo on a stick” ADCs

Finding Synergies in Combining ADCs with Multispecific Antibodies

Required adaptations to clinical trial design and execution, implemented during the COVID-19 pandemic, have put a new focus on the development of patient-focused, decentralized...

Biologics are changing the way we treat disease, affecting where companies invest, and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by the U.S. Center for Drug Evaluation and Research (CDER) were biologics, while its partner agency—the U.S. [1] Center for Biologics Evaluation and Research (CBER)—approved a dozen additional products. [2] These approvals span many modalities and cover a range of conditions, including many rare and hard-to-treat diseases.

For some time now, cancer drug developers have known “Project Optimus” and new dose optimization expectations are coming their way from the Food and...

Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...

Antibodies serve an important function in the immune system by attaching to specific molecules, or antigens, on the surface of a foreign body, such...

The stated aim of my old school is to make pupils ‘real world-ready’. This is a project conceived as one of boundless ambition in...